

Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
Copyright © 2018 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
PubReader
ePub Link
Cite this Article
| Agents | Suggested effects | References |
|---|---|---|
| Pravastatin | Reduce tubular damage in diabetic nephropathy in tubular cells and attenuate AGEs-induced apoptosis | [ |
| Atorvastatin | Inhibit AGE formation through its anti-oxidative activity | [ |
| Telmisartan | Inhibit the expression of oxidative stress and inflammatory markers by inhibiting signal transduction by AGEs and expression of arteriosclerosis-related genes | [ |
| Ramipril | Inhibit the expression of oxidative stress and inflammatory markers by inhibiting signal transduction by AGEs | [ |
| Rosiglitazone | Reduce the expression of RAGE on the myocardium and attenuate cardiac fibrosis and ventricular diastolic function | [ |
| Exendin-4 | Inhibit the AGE-RAGE mediated damage in tubular cells to attenuate the development and progression of diabetic nephropathy | [ |
| Linagliptin | Inhibit AGE-RAGE–evoked oxidative stress generation | [ |
| Aminoguanidine | Prevent cardiac hypertrophy and arterial stiffening in diabetic cardiomyopathy | [ |
| ALT-711 | AGE cross-link breaker | [ |
| Alagebrium | AGE cross-link breaker | [ |
| sRAGE | Competitive inhibitor of RAGE | [ |
AGE, advanced glycation end-product; RAGE, receptor for advanced glycation end-product; sRAGE, soluble receptor for advanced glycation end-product.
